Association Between Platelet Count as a Noninvasive Marker and Ultrasonographic Grading in Patients With Nonalcoholic Fatty Liver Disease

Garjani, Alireza; Safaeiyan, Abdolrasoul; Khoshbaten, Manouchehr

doi:10.5812/hepatmon.24449

Cited by 29 publications

(27 citation statements)

References 38 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In animal studies, a high-fat diet induced NASH mouse model exhibited elevated PIIINP [24]and Hamza et al also reported that mean serum levels of PIIINP in children with NAFLD (assessed by ultrasonography) were higher than those in control children [25].Our results are consistent with previous studies and Elevated serum PIIINP has been previously been shown to be associated with elevated pro-inflammatory cytokines in liver disease [9].PLTs have a role in thrombosis formation and evidence pointing to association between PLT count and liver injury [26]. In a study, it was reported that patients with moderate-to-severe NAFLD had higher PLT counts than milder form of NAFLD [27]and PLT count has been included in some scoring systems such as NAFLD fibrosis score [28]. In addition, platelets play a pivotal role in both hepatic regeneration and fibrosis pathophysiology and Platelets contain HGF [29],Our study also found that both PLT and HGF in NAFLD increased with the increase in severity of NAFLD, which may be the protective mechanism of the liver in the inflammatory state.…”

Section: Discussionsupporting

confidence: 90%

Serum HGF ,PCIII and PLT are Noninvasive Markers for the diagnosis of nonalcoholic fatty liver disease

Liu

Zheng

et al. 2019

Preprint

View full text Add to dashboard Cite

Background/Aims: It was suggested that serum HGF,PCIII and PLT play important roles in nonalcoholic fatty liver disease (NAFLD). Thus, we aimed to evaluate their clinical utility in the diagnosis of patients with suspected NAFLD.Methods:300 Patients with NAFLD were compared to 102 matched controls.All were subjected to history taking, anthropometric measurements, and abdominal ultrasonography, as well as laboratory assessments of liver functions, fasting lipid profile, GLU, serum PLT, HGF and PCIII.Results:The levels of HGF,PCIII and PLT were higher in NAFLD cases than controls ,and with progressive increases as the severity of fatty liver increased（P<0.05）.HGF,PCIII and PLT were correlated with various clinical parameters and severity of NAFLD（P<0.05）.The optimal cut-off values for HGF in diagnosis of mild, moderate and severe fatty liver were 14.1pg/ml(AUROC 0.753,P＝0.004), 15.4pg/ml(AUROC 0.836, P < 0.001), 17.7pg/ml(AUROC 0.903, P < 0.001). PCIII had no value in differentiate mild from moderate fatty liver ,but its ability to diagnose severe fatty liver was significant. A cut-off value for PCIII to diagnose severe fatty liver was 7.9ng/L(AUROC 0.773).The optimal cut-off values for PLT in the diagnosis of mild, moderate and severe fatty liver were 194×10^9/L(AUROC 0.732), 195×10^9/L(AUROC 0.765), 200×10^9/L(AUROC 0.925), respectively with P < 0.001. When three indicators were tested together,the AUROC(95%CI)curve for diagnose NAFLD was 0.881(sensitivity0.760,specificity 0.873)(P<0.001) .Conclusion:.Combined detection of serum HGF, PCIII and PLT may be an effective non-invasive method for diagnosing NAFLD.

show abstract

Section: Discussionsupporting

confidence: 90%

Serum HGF ,PCIII and PLT are Noninvasive Markers for the diagnosis of nonalcoholic fatty liver disease

Liu

Zheng

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Platelet count has been shown to be a valuable surrogate biomarker predicting the severity of fibrosis in NAFLD patients [39] and could be used to predict the activity of the disease [40]. …”

Section: Discussionmentioning

confidence: 99%

SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy

et al. 2019

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) has a high prevalence in obesity and its presence should be screened. Laparoscopic sleeve gastrectomy (LSG) is an effective treatment for obesity, but its effects on NAFLD are still to be firmly established. The diagnosis of non-alcoholic steatohepatitis (NASH) is currently performed by liver biopsy, a costly and invasive procedure. Squamous cell carcinoma antigen-IgM (SCCA-IgM) is a biomarker of viral hepatitis to hepatocellular carcinoma development and its role in NAFLD to NASH progression has not yet been investigated. Objective: The aim of this study was to evaluate SCCA-IgM as a non-invasive biomarker of NAFLD/NASH in patients with different degrees of metabolic-complicated obesity before and after LSG. Method: Fifty-six patients with obesity were studied before and 12 months after LSG; anthropometric, biochemical, clinical, and imaging data were collected. Results: At baseline steatosis was strongly associated with the glycaemic profile (p = 0.016) and was already present in prediabetic patients with obesity (82%). Only 3 patients had an SCCA-IgM level above the normal cut-off. SCCA-IgM titre did not change according to glycaemic profile or steatosis. Metabolic and inflammatory factors and transaminases significantly reduced after LSG-induced weight loss, except for SCCA-IgM. The ALT/AST ratio decreased post-LSG correlated with BMI (r = 0.297, p = 0.031), insulin (r = 0.354, p = 0.014), and triglycerides (r = 0.355, p = 0.009) reduction. Conclusions: Our results confirm the tight link between NAFLD and metabolic complications, suggesting prediabetes as a new risk factor of steatosis. SCCA-IgM does not seem to have a role in the identification and prognosis of NAFLD.

show abstract

“…The results from a Japanese study suggested that the platelet counts could be served as an ideal biomarker of the severity of fibrosis in NAFLD patients [ 8 ]. However, a more recent study in Iran reported that NAFLD has nothing to do with peripheral platelet counts [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study

Liu¹,

Zhou²,

Cao³

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundThe production of peripheral platelet is mainly regulated by thrombopoietin, which is a glycoprotein hormone predominantly synthesized in the liver. Previously, many studies have reported that there was an inverse correlation between the degree of chronic viral hepatitis and the peripheral platelet count. However, the effect of nonalcoholic fatty liver disease (NAFLD) on the peripheral platelet counts remains unclear.MethodsWith 1303 participants from “The prevention of MS and multi-metabolic disorders in Jiangsu province of China (PMMJS)” cohort study, we investigated the associations between NAFLD and the risk of platelet counts reduction in Chinese adults. The paired-samples T test was used to explore the platelet counts changes between baseline and follow-up. Multivariate logistic regression was used to examine the association between presence of NAFLD and the risk of platelet reduction by calculating the odds ratios (ORs) and 95% confidence interval (CI).ResultsAfter five years of follow-up, platelet counts were markedly reduced from 220.6 ± 42.22 (109/L) at baseline to 208.41 ± 40.70 (109/L) at follow-up in NAFLD group (P < 0.0001). However, platelet counts were slightly lowered from 213.2 ± 43.26(109/L) at baseline to 211.8 ± 41.65 (109/L) at follow-up in non-NAFLD people (P = 0.2349). Meanwhile, there was a significant association between NAFLD and the risks of platelet count reduction, even after adjustment for confounding variables (OR: 1.68, 95% CI: 1.06–2.67). Additionally, among the participants with BMI ≤ 23 kg/m2 and SUA ≤ 344.3 μmol/L, the NAFLD participants have an increased risk of platelet count reduction compared to the persons in non-NAFLD group.ConclusionsOur present results suggested that NAFLD individuals have an increased risk of platelet counts reduction.Electronic supplementary materialThe online version of this article (10.1186/s12944-018-0865-7) contains supplementary material, which is available to authorized users.

show abstract

Association Between Platelet Count as a Noninvasive Marker and Ultrasonographic Grading in Patients With Nonalcoholic Fatty Liver Disease

Cited by 29 publications

References 38 publications

Serum HGF ,PCIII and PLT are Noninvasive Markers for the diagnosis of nonalcoholic fatty liver disease

Serum HGF ,PCIII and PLT are Noninvasive Markers for the diagnosis of nonalcoholic fatty liver disease

SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy

Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study

Contact Info

Product

Resources

About